Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Propranolol
Drug ID BADD_D01867
Description Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors.[L6904] Propranolol is used to treat a number of conditions but most commonly is used for hypertension.[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.[L6904]
Indications and Usage Propranolol is indicated to treat hypertension.[L6907,L6904] Propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.[L6904,L6907]
Marketing Status approved; investigational
ATC Code C07AA05
DrugBank ID DB00571
KEGG ID D08443
MeSH ID D011433
PubChem ID 4946
TTD Drug ID D04JEE
NDC Product Code Not Available
UNII 9Y8NXQ24VQ
Synonyms Propranolol | Propanolol | Inderal | Avlocardyl | AY-20694 | AY 20694 | AY20694 | Rexigen | Dexpropranolol | Dociton | Obsidan | Obzidan | Propranolol Hydrochloride | Hydrochloride, Propranolol | Anaprilin | Anapriline | Betadren
Chemical Information
Molecular Formula C16H21NO2
CAS Registry Number 525-66-6
SMILES CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Coma17.02.09.0010.000588%Not Available
Completed suicide19.12.01.001; 08.04.01.0100.001923%Not Available
Condition aggravated08.01.03.0040.003755%Not Available
Confusional state19.13.01.001; 17.02.03.0050.000876%
Constipation07.02.02.0010.002276%
Cough22.02.03.0010.004514%
Crying08.01.03.005; 19.04.02.002; 17.02.05.013; 12.02.11.0010.001832%Not Available
Cyanosis23.06.04.005; 02.11.04.004; 24.03.01.007; 22.02.02.0070.001704%
Cyst08.03.05.001; 16.02.02.0020.000118%Not Available
Decreased activity19.11.01.002; 08.01.01.0060.000315%Not Available
Defect conduction intraventricular02.03.01.0180.000187%Not Available
Dementia Alzheimer's type19.20.03.001; 17.03.06.0010.000053%Not Available
Depressed level of consciousness17.02.04.0020.000588%
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis diaper23.03.04.005; 21.10.01.0160.000636%Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Developmental delay19.07.05.003; 08.01.03.0370.000053%Not Available
Diaphragmatic paralysis22.09.02.002; 17.01.04.0140.000134%Not Available
Diarrhoea07.02.01.0010.009765%
Disorientation19.13.01.002; 17.02.05.0150.000294%Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.000080%
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug hypersensitivity10.01.01.001--Not Available
Drug ineffective08.06.01.006--Not Available
Drug interaction08.06.03.0010.000625%Not Available
Drug withdrawal syndrome neonatal19.07.06.014; 18.04.13.001; 08.06.02.0080.000240%Not Available
Dry eye06.08.02.001--
Dyspepsia07.01.02.001--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene